These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18926335)

  • 41. The effect of enteric-coated aspirin on the morning increase in platelet activity.
    McCall NT; Tofler GH; Schafer AI; Williams GH; Muller JE
    Am Heart J; 1991 May; 121(5):1382-8. PubMed ID: 1902052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma".
    Cerletti C; Latini R; Del Maschio A; Galletti F; Dejana E; de Gaetano G
    Thromb Haemost; 1985 Jun; 53(3):415-8. PubMed ID: 4049312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regular and enteric coated aspirin: a reevaluation.
    Orozco-Alcala JJ; Baum J
    Arthritis Rheum; 1979 Sep; 22(9):1034-7. PubMed ID: 475872
    [No Abstract]   [Full Text] [Related]  

  • 44. Evaluation of compressibility of pentaestergum coated aspirin microcapsules.
    Pathak YV; Dorle AK
    J Microencapsul; 1989; 6(2):199-203. PubMed ID: 2723963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How reliable are enteric-coated aspirin preparations?
    Clark RL; Lasagna L
    Clin Pharmacol Ther; 1965; 6(5):568-74. PubMed ID: 5841504
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers.
    Coleman JL; Alberts MJ
    Am J Cardiol; 2006 Sep; 98(6):838-41. PubMed ID: 16950199
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enteric-coated pelletized aspirin. Gastrointestinal blood loss and bioavailability.
    Portek I; Graham G; Fleming A
    Med J Aust; 1981 Jul; 2(1):39-40. PubMed ID: 6974303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Peripheral venous plasma aspirin concentrations and platelet aggregation inhibition produced by enteric-coated aspirin formulations.
    Brandon RA; Emmett JA; Eadie MJ; Curran AC; Bunce IH
    Thromb Haemost; 1986 Apr; 55(2):222-7. PubMed ID: 3715789
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative bioavailability of aspirin from buffered, enteric-coated and plain preparations.
    Latini R; Cerletti C; de Gaetano G; Dejana E; Galletti F; Urso R; Marzot M
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):313-8. PubMed ID: 3733281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enteric coated aspirin circumventing gastric retention.
    Amidon GL; Dressman JB
    J Rheumatol; 1985 Apr; 12(2):387-8. PubMed ID: 4032418
    [No Abstract]   [Full Text] [Related]  

  • 51. Risk of gastric injury with enteric- versus nonenteric-coated aspirin.
    Banoob DW; McCloskey WW; Webster W
    Ann Pharmacother; 2002 Jan; 36(1):163-6. PubMed ID: 11816246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers.
    Blondon H; Barbier JP; Mahé I; Deverly A; Kolsky H; Bergmann JF
    Fundam Clin Pharmacol; 2000; 14(2):155-7. PubMed ID: 10796063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of enteric-coated aspirin granules with plain and buffered aspirin: a report of two studies.
    Petroski D
    Am J Gastroenterol; 1986 Jan; 81(1):26-8. PubMed ID: 3942122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial.
    Angiolillo DJ; Hwang C; Datto C; Desai B; Sostek M
    Clin Ther; 2011 Dec; 33(12):1883-93. PubMed ID: 22078153
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protection of human gastric mucosa against aspirin-enteric coating or dose reduction?
    Cole AT; Hudson N; Liew LC; Murray FE; Hawkey CJ; Heptinstall S
    Aliment Pharmacol Ther; 1999 Feb; 13(2):187-93. PubMed ID: 10102949
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Variability of response to antiplatelet therapy: what should we do next?
    Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Feb; 23(1):19-22. PubMed ID: 19267768
    [No Abstract]   [Full Text] [Related]  

  • 57. Aspirin resistance: position paper of the Working Group on Aspirin Resistance.
    Michelson AD; Cattaneo M; Eikelboom JW; Gurbel P; Kottke-Marchant K; Kunicki TJ; Pulcinelli FM; Cerletti C; Rao AK; ;
    J Thromb Haemost; 2005 Jun; 3(6):1309-11. PubMed ID: 15892858
    [No Abstract]   [Full Text] [Related]  

  • 58. [Diagnosis, causes, relevance of a complex phenomenon. Resistance to aspirin and clopidogrel].
    Mani H; Lindhoff-Last E
    Pharm Unserer Zeit; 2009; 38(4):342-50. PubMed ID: 19572355
    [No Abstract]   [Full Text] [Related]  

  • 59. Single-dose evaluation of a new enteric-coated aspirin preparation.
    Paull P; Day R; Graham G; Champion D
    Med J Aust; 1976 Apr; 1(17):617-9. PubMed ID: 933973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A trial of micro-encapsulated and enteric-coated aspirin in rheumatoid arthritis.
    Dippy JE; Pritchard MH; Lloyd KN
    Rheumatol Rehabil; 1976 May; 15(2):77-80. PubMed ID: 778989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.